Blog
RSS FeedPosted by Michael Wonder on 18 Apr 2024
FINOSE now covers all Nordic countries
18 April 2024 - Icelandic Landspitali joins the Nordic collaboration FINOSE, where HTA authorities from the Nordic countries carry out ...
Posted by Michael Wonder on 21 Nov 2023
Savings from side deals higher than previously forecast
17 November 2023 - The TLV estimates that the pharmaceutical companies will pay approximately SEK 3.33 billion in reimbursement for 2023 ...
Posted by Michael Wonder on 19 Oct 2023
Health economic assessment of Spinraza for type 5q spinal muscular atrophy
18 October 2023 - TLV has produced a health economic knowledge base for the regions for Spinraza (nusinersen sodium) for the ...
Posted by Michael Wonder on 18 Oct 2023
Health economic assessment of Beyfortus for the prevention of lower respiratory tract disease caused by respiratory syncytial virus
18 October 2023 - TLV has prepared a health economic assessment for the regions for the medicine Beyfortus (nirsevimab). ...
Posted by Michael Wonder on 16 Oct 2023
Health economic assessment of Enhertu in breast cancer
13 October 2023 - TLV has produced a health economic assessment of Enhertu (trastuzumab deruxtecan) for the regions. ...
Posted by Michael Wonder on 12 Oct 2023
Health economic assessment of the gene therapy Hemgenix in severe and moderate haemophilia B
11 October 2023 - TLV has developed a health economic knowledge base for the regions for the gene therapy Hemgenix (etranacogene ...
Posted by Michael Wonder on 09 Oct 2023
TLV believes that the requirements for evidence in new EU legislation must be strengthened
9 October 2023 - The European Commission's proposal for a new regulation and directive has a decisive impact on the quality ...
Posted by Michael Wonder on 05 Oct 2023
New payment models are needed to finance new advanced treatments
29 September 2023 - Pricing and subsidy methods and processes need to be developed to address the challenges that arise when ...
Posted by Michael Wonder on 05 Jul 2023
TLV is tasked with carrying out health economic assessments of new drugs against cancer
4 July 2023 - The TLV shall carry out health economic assessments of new drugs to be used in clinics, ...
Posted by Michael Wonder on 21 Jun 2023
Imbruvica is included in the high-cost protection with a changed benefit limitation
19 June 2023 - Ibrutinib (Imbruvica)140 mg, 280 mg & 420 mg tablets are now subsidised for the treatment ...
Posted by Michael Wonder on 18 Jun 2023
Health economic assessment of Carvykti in the treatment of multiple myeloma
16 June 2023 - TLV has prepared a health economic assessment for the regions for Carvykti (ciltacabtagene autoleucel). ...
Posted by Michael Wonder on 14 Jun 2023
Health economic assessment of Pluvicto in advanced prostate cancer
12 June 2023 - TLV has produced a health economic assessment for the regions for Pluvicto (Lutetium Lu 177 vipivotide tetraxetan). ...
Posted by Michael Wonder on 13 Jun 2023
The Supreme Administrative Court did not test Mayzent
12 June 2023 - The Supreme Administrative Court decided on 3 May not to grant a review permit for Mayzent. ...
Posted by Michael Wonder on 14 May 2023
The FINOSE collaboration is extended and strengthened by the entry of the Danish Medicines Council
11 May 2023 - On 10 May 2023, the Nordic HTA collaboration FINOSE was extended for another three years and the ...
Posted by Michael Wonder on 04 Apr 2023
TLV reconsiders the subsidy of Lumykras (sotorasib)
4 April 2023 - TLV has started a review of Lumykras (sotorasib). Lumykras (sotorasib) has already been included in the high-cost ...